TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies

Haematologica. 2019 Aug;104(8):e345-e348. doi: 10.3324/haematol.2018.205302. Epub 2019 Feb 21.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Biomarkers, Tumor
  • Decitabine / administration & dosage
  • Decitabine / adverse effects
  • Decitabine / therapeutic use*
  • Female
  • Humans
  • Immunohistochemistry
  • Leukemia, Myeloid / diagnosis
  • Leukemia, Myeloid / drug therapy*
  • Leukemia, Myeloid / genetics*
  • Male
  • Mutation*
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / metabolism
  • Myelodysplastic Syndromes / pathology
  • Treatment Outcome
  • Tumor Suppressor Protein p53 / genetics*
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers, Tumor
  • Tumor Suppressor Protein p53
  • Decitabine